Financial Performance - Revenue increased by approximately 3.3% to RMB 772.9 million (2024: RMB 747.9 million) [3] - Gross profit rose by about 5.2% to RMB 566.2 million (2024: RMB 538.3 million) [3] - Profit for the year was RMB 24.7 million (2024: RMB 34.6 million) [3] - Earnings per share decreased to RMB 2.61 (2024: RMB 3.65) [3] - Total comprehensive income for the year amounted to RMB 22.9 million (2024: RMB 16.0 million) [4] - Other income and gains increased to RMB 8.2 million (2024: RMB 6.7 million) [4] - Selling and distribution expenses rose to RMB 460.9 million (2024: RMB 408.6 million) [4] - Administrative expenses decreased to RMB 80.9 million (2024: RMB 88.6 million) [4] - The company reported a foreign exchange loss of RMB 1.8 million (2024: RMB 18.5 million) [4] Assets and Liabilities - Total assets increased to RMB 603,463,000 (approximately USD 85.5 million) in 2025 from RMB 505,557,000 in 2024, representing a growth of 19.4% [5] - Current assets rose to RMB 392,844,000 in 2025, up from RMB 287,331,000 in 2024, marking an increase of 36.8% [5] - Non-current assets totaled RMB 210,619,000 in 2025, a slight decrease from RMB 218,226,000 in 2024, reflecting a decline of 3.0% [5] - Total liabilities increased to RMB 146,527,000 in 2025, compared to RMB 69,139,000 in 2024, indicating a significant rise of 112.5% [5] - Net assets reached RMB 456,936,000 in 2025, up from RMB 436,418,000 in 2024, showing an increase of 4.0% [6] - The company's equity attributable to owners remained stable at RMB 416,959,000 in 2025, compared to RMB 394,096,000 in 2024, reflecting a growth of 5.8% [6] - Cash and cash equivalents surged to RMB 182,323,000 in 2025 from RMB 104,530,000 in 2024, representing a substantial increase of 74.5% [5] - Trade receivables increased to RMB 53,305,000 in 2025, up from RMB 41,902,000 in 2024, which is a growth of 27.0% [5] Market and Operations - The company operates primarily in China, Australia, and New Zealand, focusing on the manufacturing and sales of nutritional dietary supplements and health foods [8] - Revenue from the Chinese market for 2025 is RMB 649,298 thousand, compared to RMB 623,538 thousand in 2024, indicating a growth of about 4.1% [13] - The group launched 27 new products in 2025, including 23 from the Good Health series and 4 from the Living Nature series [38] - The group continued to enhance its cross-border e-commerce marketing strategy, contributing to revenue growth from the Good Health brand [40] Cost and Expenses - The cost of goods sold for 2025 is RMB 203,763 thousand, slightly decreased from RMB 206,318 thousand in 2024, a reduction of about 1.3% [20] - The group reported a pre-tax profit margin for 2025, with total expenses including employee benefits amounting to RMB 110,414 thousand, up from RMB 98,354 thousand in 2024, an increase of approximately 12.3% [20] - Sales and distribution expenses increased by approximately 12.8% from about RMB 408.6 million in 2024 to about RMB 460.9 million in 2025, accounting for 59.6% of revenue [43] - Administrative expenses decreased from approximately RMB 88.6 million in 2024 to about RMB 80.9 million in the current year, representing a reduction of about 8.7% [44] Tax and Earnings - The total income tax expense for the year 2025 is CNY 2,100,000, while for 2024 it was CNY 6,320,000, reflecting a significant decrease [24] - The basic earnings per share for the year 2025 is CNY 24,665, compared to CNY 34,562 for 2024, indicating a decline in profitability [28] Inventory and Receivables - The company's total inventory for 2025 is CNY 77,636,000, down from CNY 119,085,000 in 2024, showing a reduction in stock levels [30] - Trade receivables for 2025 amount to CNY 56,431,000, an increase from CNY 45,429,000 in 2024, indicating growth in sales on credit [31] Dividends and Share Structure - The board does not recommend the payment of any final dividend for the year (2024: none) [3] - The average number of ordinary shares outstanding for both 2025 and 2024 is 946,298,370 shares, indicating no change in share structure [26] Future Outlook and Strategy - The global economy is expected to show some resilience in 2025, but growth momentum remains insufficient amid geopolitical tensions and trade protectionism [56] - The Chinese health consumption market is transitioning from "discretionary spending" to "essential demand," driven by a large population and increasing health awareness [58] - The group aims to focus on the "Good Health" brand core and continue rapid growth in the cross-border e-commerce nutrition supplement market while emphasizing quality and operational efficiency [59] - The group plans to deepen e-commerce channel promotion and enhance marketing effectiveness by optimizing input-output structures and collaborating with platforms like Xiaohongshu and Douyin [60] - Continued investment in R&D will focus on product innovation around "functional differentiation," "ingredient precision," and "convenient forms," catering to various health needs across different age groups [61] - The group will expand its overseas network while solidifying its presence in core markets like New Zealand and Australia, and actively explore emerging markets in Southeast Asia [62] - The management is confident in the long-term development prospects of the Chinese health consumption market, aiming to create greater value for shareholders through market insights and effective operational management [63] Employment and Governance - As of December 31, 2025, the group employed 524 staff, with total salary and related costs approximately RMB 129.6 million, an increase from RMB 120.8 million in the previous year [64] - The company has established an Audit Committee consisting of three independent non-executive directors, responsible for overseeing financial reporting and risk management [69] - The financial statements for the year have been audited by Ernst & Young, confirming the accuracy of the reported figures [70] - The Annual General Meeting is scheduled for June 5, 2026, with a record date for voting rights set for June 1, 2026 [72][73] - The annual results announcement will be published on the Hong Kong Stock Exchange website and the company's website [74]
中生联合(03332) - 2025 - 年度业绩